The tumor-agnostic FDA approval of T-DXd for HER2-positive unresectable or metastatic solid malignancies exemplifies the importance of understanding the risks associated with targeted therapy and the need for proactive monitoring strategies.
Thomas Bokinz, PharmD
Advertisement
Articles by Thomas Bokinz, PharmD
Advertisement
Latest Updated Articles
Precision Oncology: Expanding Therapeutic Horizons With Trastuzumab DeruxtecanPublished: December 3rd 2024 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
States Push Forward on Insurance Mandates for GLP-1 and Obesity Treatments
2
Clinical Data Support Use of Low-Carbon Version of Albuterol Metered Dose Inhaler for Asthma
3
FDA Expands Approval of Sotatercept-Csrk for Pulmonary Arterial Hypertension
4
Expert Insights on Key Data from IMS 2025
5
